<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab2">
 <label>Table 2</label>
 <caption>
  <p>Overview of main results of integrated models</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Group</th>
    <th>Author/year of publication</th>
    <th>Disease</th>
    <th>Study design</th>
    <th>Number of individuals</th>
    <th>Loss-to-follow-up (%)</th>
    <th>Main results</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="6">Interventions with opioid agonist treatment</td>
    <td>Achmad, Y.M. et al (2009)</td>
    <td>HIV</td>
    <td>Cohort</td>
    <td>223</td>
    <td>No difference between the intervention group and the control group. No data are available.</td>
    <td>Virological response (HIV viral load): IG: 97 % versus CG: 90 %, p = 0.27
     <break/>Immunological response (CD4 cell count): IG: 69 % versus CG: 57 %, p = 0.93.
    </td>
   </tr>
   <tr>
    <td>Batki, S.L. et al (2002)</td>
    <td>TB</td>
    <td>RCT</td>
    <td>111</td>
    <td>52%</td>
    <td>TBC completion (≥ 80 % of the doses administrated): 59.5 % in Standard Methadone Treatment, 77.1 % in Minimal Methadone Treatment and 13.1 % in Routine Care, p &lt; 0.01.</td>
   </tr>
   <tr>
    <td>Bruce, D.R. et al (2012)</td>
    <td>HCV</td>
    <td>RCT</td>
    <td>21</td>
    <td>67%</td>
    <td>SVR: Six of ten in the intervention group and one of four in the control group, achieved SVR</td>
   </tr>
   <tr>
    <td>Lucas, G.M. et al (2010)</td>
    <td>HIV</td>
    <td>RCT</td>
    <td>93</td>
    <td>17%</td>
    <td>HIV RNA and CD4 cell count: No significant differences between opioid agonist therapy in the clinic-based buprenorphine strategy versus specialized opioid treatment program were found (p = 0.31 and p = 0.16, respectively)</td>
   </tr>
   <tr>
    <td>Morozova, O. et al (2013)</td>
    <td>TB</td>
    <td>Cohort</td>
    <td>110</td>
    <td>18 %</td>
    <td>Treatment completion: IG: 90 % versus CG: 74 %, p = 0.03.</td>
   </tr>
   <tr>
    <td>Tetrault, J.M. et al (2012)</td>
    <td>HIV</td>
    <td>RCT</td>
    <td>47</td>
    <td>30%</td>
    <td>Virological response (HIV viral load): Descreased from 58 % at baseline to 43 % at 12 weeks in IG, and from 56 % to 35 % in CG, p = 0.84 and p = 0.27, respectively.</td>
   </tr>
   <tr>
    <td rowspan="4">Interventions without opioid agonist treatment</td>
    <td>Groessl, E.J. et al (2017)</td>
    <td>HCV</td>
    <td>RCT</td>
    <td>79</td>
    <td>37%</td>
    <td>SVR: 67 % in IG versus 55 % in CG, p = 0.23.</td>
   </tr>
   <tr>
    <td>Ho, S.B. et al (2015)</td>
    <td>HCV</td>
    <td>RCT</td>
    <td>363</td>
    <td>53%</td>
    <td>SVR: 16 % and 8 % in IG and in CG, respectively, achieved SVR. OR 2.26 (95 % CI: 1.15-4.44, p = 0.02)
     <break/>SVR (active substance users and alcohol dependents): IG: 11 % versus CG: 7 %, p = 0.49.
    </td>
   </tr>
   <tr>
    <td>Sánchez, G.C. et al (2012)</td>
    <td>HIV</td>
    <td>Cohort</td>
    <td>119</td>
    <td>In IG 13 % versus in CG 8 % permanently discontinued treatment.</td>
    <td>Virological response (HIV RNA load &lt; 50 copies/mL) at week 48: 93 % (95 % CI = 87 % - 99 %) in IG versus 94 % (95% CI = 84 % - 100 %) in CG.
     <break/>Virological response (HIV RNA load &lt; 50 copies/mL) at week 96: 87 % (95 % CI = 79 % - 95 %) in IG, and 88 % (95% CI = 78 % - 97 %) in CG.
     <break/>No significant differences were found, Kaplan-Meier estimates, log rank test, p =0.965.
    </td>
   </tr>
   <tr>
    <td>Simoni, J.M. et al (2007)</td>
    <td>HIV</td>
    <td>RCT</td>
    <td>136</td>
    <td>All recruited were followed up, but only 59 % at baseline, 65 % at three months, and 61 % at six months reported adherence on 95 % or more.</td>
    <td>HIV RNA: HIV suppression was not found significantly different between the integrated group and the control group at baseline, three months and six months follow up.</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>Abbreviations: CG</italic> Control group, 
   <italic>HCV</italic> Hepatitis C virus, 
   <italic>HIV</italic> Human immunodeficiency virus, 
   <italic>IG</italic> Intervention group, 
   <italic>RCT</italic> Randomized controlled trial, 
   <italic>SD</italic> Standard deviation, 
   <italic>SUD</italic> Substance use disorder, 
   <italic>SVR</italic> Sustained virological response, 
   <italic>TB</italic> Mycobactrium tuberculosis
  </p>
 </table-wrap-foot>
</table-wrap>
